Aqr Capital Management LLC Bei Gene, Ltd. Transaction History

Aqr Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $9.04 Million - $16.5 Million	-72,021 Reduced 92.92%	5,486 $1.21 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $13,707 - $21,032	-104 Reduced 0.13%	77,507 $10.4 Million
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $41,298 - $73,673	-341 Reduced 0.44%	77,611 $12.6 Million
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $106,813 - $196,509	-729 Reduced 0.93%	77,952 $14.7 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $555,531 - $870,174	-2,235 Reduced 2.76%	78,681 $21.3 Million
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $128,044 - $206,810	-513 Reduced 0.63%	80,916 $29.4 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $6,440 - $8,074	22 Added 0.03%	81,429 $27.9 Million
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $4.93 Million - $7.23 Million	18,914 Added 30.27%	81,407 $28.3 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $13.8 Million - $19.8 Million	62,493 New	62,493 $16.1 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.